Article Information
History
- April 8, 2020.
Article Versions
- You are currently viewing Version 1 of this article (April 8, 2020 - 08:12).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Maximilian F. Konig1,2,
- Mike Powell3,
- Verena Staedtke4,
- Ren-Yuan Bai5,
- David L. Thomas6,
- Nicole Fischer7,
- Sakibul Huq5,
- Adham M. Khalafallah5,
- Allison Koenecke8,
- Nickolas Papadopoulos1,
- Kenneth W. Kinzler1,
- Bert Vogelstein1,
- Joshua T. Vogelstein3,*,
- Susan Athey9,*,
- Shibin Zhou1,* and
- Chetan Bettegowda1,5,*
- 1Ludwig Center, Lustgarten Laboratory, and the Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
- 2Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 3Department of Biomedical Engineering, Institute of Computational Medicine, The Johns Hopkins University, Baltimore, MD, USA
- 4Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 5Department of Neurosurgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 6Division of Infectious Diseases, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 7The Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 8Institute for Computational & Mathematical Engineering, Stanford University, Stanford, CA, USA
- 9Stanford Graduate School of Business, Stanford University, Stanford, CA, USA
- ↵*To whom correspondence should be addressed. cbetteg1{at}jhmi.edu
Posted April 08, 2020.
Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome
